Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...197198199200201202203204205206207208209»
  • ||||||||||  Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma, Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
    New P1 trial:  The Drug-drug Interaction of SHR3824 and SP2086 (clinicaltrials.gov) -  Jul 16, 2015   
    P1,  N=12, Recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion, Trial primary completion date:  Dose-Escalation and Safety Trial of YN968D1 (clinicaltrials.gov) -  May 14, 2015   
    P1/2,  N=50, Completed, 
    Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Feb 2015
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    New P1 trial, First-in-human:  First-in-Human Single Ascending Dose of SHR0302 (clinicaltrials.gov) -  Apr 22, 2015   
    P1,  N=64, Recruiting, 
  • ||||||||||  Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
    Trial completion:  A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers (clinicaltrials.gov) -  Apr 6, 2015   
    P1,  N=96, Completed, 
    Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Feb 2015 Recruiting --> Completed
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion, Enrollment change, Trial primary completion date:  A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Apr 3, 2015   
    P2,  N=121, Completed, 
    Recruiting --> Completed | Initiation date: Jul 2011 --> Apr 2011 | Trial primary completion date: Jul 2012 --> Nov 2014 Recruiting --> Completed | N=36 --> 121 | Trial primary completion date: Dec 2010 --> Jul 2013
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial primary completion date:  Dose-Escalation and Safety Trial of YN968D1 (clinicaltrials.gov) -  Jan 15, 2015   
    P1/2,  N=42, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Apr 2013 --> Jun 2015
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial primary completion date:  Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients (clinicaltrials.gov) -  Dec 29, 2014   
    P2a,  N=60, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Mar 2015
  • ||||||||||  Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
    Trial completion:  CyclASol (clinicaltrials.gov) -  May 18, 2014   
    P1,  N=18, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Sep 2015 Active, not recruiting --> Completed
  • ||||||||||  Trial completion:  NovaTears (clinicaltrials.gov) -  May 18, 2014   
    P=N/A,  N=30, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
    New P1 trial:  CyclASol (clinicaltrials.gov) -  Apr 10, 2014   
    P1,  N=18, Active, not recruiting,